Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796676 · ClinicalTrials.gov registry record · Phase 3
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 287
- Enrollment target
NCT03796676 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 287 participants.
The verdict
NCT03796676, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 287 participants
- Enrollment target
Study Summary
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to \<18 years of age with moderate to severe AD.
Interventions
- DRUG Placebo
- DRUG PF-04965842
- DRUG PF04965842
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2019-02-18 |
| Est. Completion | 2020-04-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03796676
The ClinicalTrials.gov registry entry for NCT03796676 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03796676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03796676 about?
NCT03796676 is a clinical study titled "JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis". This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to \<18 years of age with moderate to severe AD.
What is the current status of trial NCT03796676?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 287 participants. The study started on 2019-02-18. Estimated completion is 2020-04-08.
What interventions are being tested in trial NCT03796676?
The interventions under investigation include: Placebo (DRUG), PF-04965842 (DRUG), PF04965842 (DRUG).
Who is sponsoring clinical trial NCT03796676?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.